

## CURRICULUM VITAE

**NAME: THEONI TRANGAS**

### **i) EDUCATION / ACADEMIC TITLES:**

- 1972**                    **Bachelor of Arts in Biology B.A.**  
Wilson College, Chambersburg, PA, USA
- 1974**                    **Master of Arts in Biology**  
Bryn Mawr College, Bryn Mawr, PA, USA  
Title: Studies on the Intracellular Ribonucleases B of *Tetrahymena pyriformis* W
- 1977**                    **Ph.D. in Biology and Biochemistry**  
Bryn Mawr College, Bryn Mawr, PA, USA  
Dissertation Title: Characterization of Three Intracellular Ribonucleases from *Tetrahymena pyriformis* W
- 1991-1994**            **Associate Professor of Biochemistry (Research)**  
University of North Carolina, School of Medicine, Chapel Hill, N.C, USA
- 2001-2003**            **Associate Professor (Visiting)**  
Dept. of Molecular Biology and Genetics  
Democritus University of Thrace, Alexandroupolis, Greece
- 2006-**                    **Assoc. Professor in Biochemistry**  
Department of Biological Applications and Technologies  
University of Ioannina,  
Ioannina Greece

### **OCCUPATION:**

- 1978 -1987**            **Research Associate**  
“G.Papanikolaou” Research Center  
“St Savvas “ Cancer Hospital Athens Greece
- 1987-1990**            **Research Scholar,**  
Biochemistry Dept., Medical School  
University of Kentucky, USA
- 1991-1994**            **Visiting Professor**  
Dept. of Biochemistry and Biophysics  
Medical School, University of North Carolina, USA
- 1996- 2006**            **Supervisor Molecular Genetics**  
Genetics Dept, “G. Papanikolaou” Research Center,  
“ St Savvas” Cancer Hospital, Athens, Greece

- 2001- 2002**                    **Associate Professor (Visiting)**  
 Dept. of Molecular Biology and Genetics  
 Democritus University of Thrace  
 Alexandroupolis, Greece
- 2005-**                            **Head of Molecular Genetics section,**  
**BioAnalytica-GenoType S.A.**
- 2006-**                            **Assoc. Professor in Biochemistry**  
 Department of Biological Applications and Technologies  
 University of Ioannina, Ioannina, Greece

**AWARDS FELLOWSHIPS:**

- 1968-1972**                    Student Scholarship  
 Wilson College, PA, USA
- 1974 -1975**                    Marguerite Farley Fellowship  
 Bryn Mawr College, PA, USA
- 1975-1976**                    Graduate Student Fellowship  
 Bryn Mawr College, PA, USA
- 1987-1988**                    Eleanor Roosevelt Cancer Research Fellowship,  
 International Union Against Cancer (UICC),  
 American Cancer Association
- 1988-1989**                    Fogarty Fellowship    National Institutes of Health USA

**RESEARCH ACTIVITY:**

**Doctoral Theses in progress**    Ch. Meristoudis  
 “ Study of trans acting and cis acting factors in the posttranscriptional regulation of c-myc mRNA”  
 M Devetzi .  
 «Study of the of Tissue Kallikerins 7 and 14 in Colon Cancer progress”  
 E. Gourgouveli  
 “Genetic Characteristics correlating with disease progression in Myelodysplastic syndroms”  
 D. Iakovaki  
 Genetic components underlying phenotypic heterogeneity in Multiple Myeloma

**Publications**                    **45 original research articles in peer reviewed Journals**  
 4 book chapters - Reviews  
 70 conference abstracts  
 4 entries in Data banks

**Citations**                        820 h-factor 17

iii)

**Invited Reviews after 2001:**

Ioannidis P and **T .Trangas (2004)** CRD-BP/IMP1: AN RNA BINDING PROTEIN WITH TUMORIGENIC CHARACTERISTICS "Progress in RNA Research Nova Science Publishers, pp. 39-71

**Trangas T**, Ioannidis P. IGF2BP1 (insulin-like growth factor 2 mRNA binding protein 1). Atlas Genet Cytogenet Oncol Haematol. November 2010.

**Invited Talks after 2001:**

- May 2013 1st conference of Hellenic Society of Clinical Geneticists RNA binding proteins Cytoplasmic regulators of Gene Expression“
- December 2010 Cancer: Training. Research and Clinical Practice Conference “Over diagnosis and Overtreatment vs. UnderDiagnosis and Undertreatment -A Molecular Biologist View”
- September 2008 Seminar Genetics Laboratory Accreditation Greek Chemists Union
- November 2007 Panhellenic Anticancer Conference “Molecular Genetics of Cancer”
- November 2005 Greek Surgical Society “Molecular consequences of chromosomal aberrations in cancer”

**Reviewer in Scientific Journals:**

- International Journal of Cancer
- Oncogene
- Genes and Cancer
- Pigment Cell & Melanoma Research
- Tumor Biology

**In National and European Organizations:**

1. Secreteriat of Research and Tecnology Ministry of Research and Technology
  - International collaboration programs
  - PENED ,
  - SYN
2. University of Patras
  - Karatheodori´s Grant

**Editorial Board:**

International Journal of Biological Markers 2005  
ISRN Oncology

**Organization member:**

- Greek Society of Biochemistry and Molecular Biology
- SIGE Hellenic Association of Medical Geneticists
- Clinical Chemistry Union
- Periktioni Women Researcher Network (Founding member)

**European**

**Network  
2009-2013**

- Cost action European Genomics and Epigenomics Study on MDS and AML National Representative

iv)

**GRANTS after 2001**

**1999-2001**

National Program on Improvement of Research Human Resources (PENED 1999), , Greek Secretariat of Research and Technology/ Greek Ministry of Development “ Detection and Identification of Genetic Alterations –Markers in Neoplasms of Unknown primary origin”  
70,000,000 Drachmas  
Researcher

**2002-2003**

ENTER- General Secretariat of Research and Technology7 Greek Ministry of Development,  
“ Cancer Markers New Approaches for Evaluation”  
73,250 Euro  
Researcher

**2003-2004**

National Program PRAXE A, Greek Secretariat of Research and Technology/ Greek Ministry of Development EPAN 4.1.1 Research team support for the validation and commercial use of research results for the establishment of Spin Off Companies »  
Research and application Services in Molecular Cytogenetics  
44,000 Euro

**2004-2007**

PYTHAGORAS , Greek Secretariat of Research and Technology/ Greek Ministry of Development  
«Study of vitamin D receptor in osteosarcoma”  
44,000 Euro  
Researcher

**2005-2007**

National Program PRAXE B, Greek Secretariat of Research and Technology/ Greek Ministry of Development EPAN 4.1.1 Research team support for the validation and commercial use of research results for the establishment of Spin Off Companies »  
Research and application Services in Molecular Cytogenetics  
Start up activities  
700,000 Euro  
Collaborator

**2011-2014**

HRAKLEITOS II, Greek Secretariat of Research and Technology/ Greek Ministry of Development , Support of human research resources through financing doctoral thesis research “Study of Kallikreins 7 and 14 in Colon Cancer”  
40,000 Euro  
Principal Investigator

## PUBLICATIONS

1. Tsiapalis, CM, **Trangas, T** and Gounaris, A. (1982). Phosphorylation and Activation of poly (A) endonuclease from Calf Thymus Gland. *FEBS Letters* **140**: 213-218.  
Impact factor<sup>1</sup> **3,44**
2. Papamichail, M, **Trangas, T**, Courtis, N, Ioannides, C, Cosmidou, H, Pangalis, GA, and Tsiapalis, CM (1983) Poly (A) polymerase activity levels in Leukemia *Haematol Bluttransfus.* **28**: 28-29.  
Impact factor -
3. **Trangas, T**\*, Courtis, N, Pangalis, GA, Cosmides, H. Ioannides, C, Papamichail, M and Tsiapalis C.M (1984) Polyadenylic Acid Polymerase in Normal and Leukemic Human Leukocytes. *Cancer Research* **44**: 3691-3697.  
Impact factor: **8,460**
4. Pangalis, GA, **Trangas, T**, Roussou, PA and Tsiapalis, CM (1985) The value of Poly (A) polymerase as a prognostic biochemical marker in chronic lymphocytic leukemia. *Acta Haematologica* **74**: 31-34.  
Impact factor: **0,899**
5. Kokkinopoulos, D, **Trangas, T**, Perez, S, Tsiapalis, CM and Papamichail, M (1986) Dexamethasone Induced Alterations in Poly (A) polymerase Levels in a Human Leukemic Cell Line. *Leukem. Res.* **10**: (11) 1341-1345.  
Impact factor **2,764**
6. Perez, S, **Trangas, T**, Kokkinopoulos, D, Tsiapalis, CM and Papamichail, M (1987) Poly (A) metabolizing enzyme levels during induction of differentiation in human Leukemic T Cell line with Phorbol Ester *J.Natl Canc. Inst.* **78**:407-411.  
Impact factor: **14,160**
7. Gounaris, A, **Trangas, T** and Tsiapalis, CM (1987) Soluble cAMP-independent protein kinase activity from human spleen. *Arch. Biochem. Biophys.* **259**: 473-480.  
  
Impact factor: **2,576**
8. Courtis, N, **Trangas, T** and Tsiapalis, CM (1987) Increase in the levels of Activity of polyadenylic acid Metabolizing Enzymes following phytohaemagglutinin stimulation of Human Lymphocytes. *Mol. Cel. Biochem.* **75**: 3 -42.  
Impact factor: **2, 329**
9. Perez, S, Courtis, N, Kokkinopoulos D, Papamichail, M, Tsiapalis, CM and **Trangas, T**\* (1987) A colorimetric assay for the determination of 5' nucleotidase activity. *J. Immun. Methods* **101**: 73- 78.  
Impact factor: **1,995**
10. Gounaris, A, Courtis, N, Pangalis, GA, Tsiapalis, CM and **Trangas, T** (1988) Relation

---

\* corresponding author

between the activity of poly(A)polymerase and the levels of protein synthesis in the lymphocytes of patients with chronic lymphocytic leukemia. *Blut* **57**: 293-296.

*Impact factor:*

11. Courtis, N, **Trangas, T**, Pangalis, GA and Tsiapalis, CM (1988) Correlation of poly (A) polymerase activity and adenosine deaminase activity levels with the cytotoxic effects of cofomycin and 2-deoxycoformycin in cultured lymphocytes from patients with chronic lymphocytic leukemias. *Clin. Chem. Enzym. Commun.* **1**: 187- 193.

*Impact factor:*

12. **Trangas, T**, Courtis, N, Gounaris, A, Perez, S, Kokkinopoulos, D, Pangalis, GA and Tsiapalis, CM (1988) Patterns of adenosine deaminase, ecto-5'-nucleotidase, poly(A)polymerase and surface light chain expression in chronic lymphocytic leukemias. *Blut* **58**: 187-193.

13. **Trangas, T** and Coleman, MS (1989) Tissue-specific expression of human Terminal Deoxynucleotidyl Transferase is regulated at the Transcriptional level. *Biochem. Biophys. Res. Commun.* **164**: 750-757.

*Impact factor: 3,055*

14. Scorilas, A, Yiotis, J, Gouriotis, D, Keramopoulos, A, Ampelas, A, **Trangas, T** and Talieri, M (1993) Cathepsin-D and c-erb-B2 have an additive prognostic value for breast cancer patients. *Anticancer Res.* **13**: 15861-15867.

*Impact factor: 1,33*

15. Bhaumik, D, Yang, B, **Trangas, T**, Coleman MS and Sorscher, DH (1994) Identification of a Tripartite Basal Promoter Which Regulates Human Terminal Deoxynucleotidyl Transferase Gene Expression. *Journal Biol. Chem.* **269** :15861-15867.

*Impact factor: 7,368*

16. Sorscher, DH, Yang, B, Bhaumik, D., **Trangas, T**, Phillips, AV, Chancellor, KE and Coleman, MS (1994) Initiation of Transcription at the Human Terminal Deoxynucleotidyl Transferase Gene Promoter: A Novel Role for the TATA binding protein. *Biochem.* **33**: 1105- 11032.

*Impact factor: 4,221*

17. Scorilas, A, Yotis, J, Stravolemos, K, Gouriotis, D, Keramopoulos, A, Ampela, K, Talieri, M and **Trangas, T** \*(1995) C-erb- B2 overexpression May be Used as an Independent prognostic Factor for Breast Cancer Patients. *Anticancer Res.* **15**: 1543-1548.

*Impact factor: 1, 71*

18. Ioannidis, P, Havredaki, M, Courtis, N, **Trangas, T\*** (1996) *In vivo* generation of 3' and 5' truncated species in the process of c-myc mRNA decay. *Nucleic Acids Research* **27**: 4969-4977.

*Impact factor: 8,278*

19. Sotiriadou, R, Kokkinopoulos, D, Stinios, J, Dimas, C, **Trangas T** and Perez, S (1996) delta IK 17: an antigen expressed in human lymphocytes. *Int J Biol Markers* **11**: 183-189.

*Impact factor: 1,292*

20. Perez, S, Sotiriadou, R, Missitzis, G, **Trangas T**, Gianoulis, N, Mavroudeas, D,

Apostolikas, N and Kokkinopoulos, D (1996) delta IK 17 antigen: a possible early marker of cancer development. *Int J Biol Markers* **11** : 190-7.  
*Impact factor: 1,292*

21.Scorilas, A, Courtis, N, Talieri, M, Yotis, J, Michailakis, E and **Trangas, T**\*(1998) Poly (A) polymerase activity levels in breast tumour cytosols. *J. Exper. Clin. Cancer Res.* **17**: 511-518.

*Impact factor: 0,54*

22.Ioannidis, P, Courtis, N, Havredaki, M, Tsiapalis, CM, Michailakis, E and **Trangas, T** \*(1999) The polyadenylation inhibitor cordycepin (3'dA) causes a decline in c-MYC mRNA levels without affecting c-MYC protein levels. *Oncogene* **18**: 117-125.

*Impact factor 7,37*

23.Scorilas, A, Yotis, J, Pateras, C, **Trangas, T** and Talieri, M (1999) Predictive value of c-erbB-2 and Cathepsin D for Greek Breast Patients Using Univariate and Multivariate Analysis. *Clin. Cancer Res.* **5**: 815-821.

*Impact factor: 4,643*

24.Scorilas, A, **Trangas, T**, Yotis, J, Pateras, C and Talieri, M (1999) Determination of c-myc amplification and overexpression in breast cancer patients and its prognostic value against c-erbB-2, cathepsin, D and clinicopathological factors using Univariate and multivariate analysis *Br.J.Cancer* **81**: 1385-1391.

*Impact factor: 4, 635*

25.Scorilas, A, Talieri, M, Ardavanis, A., Courtis, N, Dimitriadis, E, Yotis, J, Tsiapalis, CM and **Trangas, T** \*(2000) Polyadenylate Polymerase Enzymatic Activity in Mammary Tumor Cytosols: A New Independent Prognostic Marker in Primary Breast Cancer. *Cancer Res.* **60**: 5427-33.

*Impact factor: 8,460*

26.Dimas, K, Demetzos, C, Vaos, V, Ioannidis, P and **Trangas, T** (2001) Labdane type diterpenes downregulate the expression of c-myc protein but not bcl-2 in human leukemia T cells undergoing apoptosis. *Leukemia Res.* **25**: 449-54.

*Impact factor 2,764*

27.Scorilas, A, Karameris, A, Arnogiannaki, N, Ardavanis, A, Vasilopoulos, P, **Trangas, T** and Talieri M (2001) Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients *Br.J.Cancer* **84**: 1488-1496.

*Impact factor: 3,489*

28.Ioannidis, P, **Trangas, T**,\* Dimitradis, E, Samiotaki, M, Kyriazoglou, I, Tsiapalis, CM, Kittas, C, Agnantis, N, Nielsen, FC, Nielsen, J, Christiansen, J and Pandis, N (2001). C-MYC and IGF-II mRNA binding Protein (CRD-BP/IMP-1) in Benign and Malignant Mesenchymal Tumors *Int. J.Cancer* **94**: 480-484.

*Impact factor: 6,18*

29.Ioannidis P, Mahaira L, Papadopoulou A, Teixeira M, Evangelou E Dafni, U, Andersen JA, Heim S, Pandis, N, Trangas, T. (2003) 8q24 Copy Number Gains and Expression of c-myc mRNA Stabilizing Protein CRD-BP in Primary Breast Carcinomas *Int J Cancer.* ; **104**(1): 54-9.

*Impact factor: 6,18*

30. Pantou D., Tsarouha H, Papadopoulou A, Mahaira L, Kyriazoglou I, Apostolikas N, Markidou S, **Trangas T**, Pandis N, Bardi G (2003) Cytogenetic profile of unknown primary tumors: Clues for the Pathogenesis and Clinical Management *Neoplasia*: 5(1):23-31.

*Impact factor: 5, 47*

31. Papadopoulou A, **Trangas T**, \* Teixeira MR, Heim S, Dimitriadis E, Tsarouha H, Andersen JA, Evangelou E, Ioannidis I, Agnantis N and Pandis N (2003) Telomerase activity and genetic alterations in primary breast carcinomas. *Neoplasia*: 5 170-8.

*Impact factor: 5, 47*

32. Ioannidis P., Mahaira L, Papadopoulou A., Teixeira MR, Heim S, Andersen A, Evangelou E, Dafni U, Pandis N, **Trangas T** (2003) CRD- BP: a c-myc mRNA stabilizing protein with an oncofetal pattern of expression *Anticancer Research* 23: 2179-2183.

*Impact factor: 1, 71*

33. Ioannidis P, Kottaridi C, Dimitriadis E, Courtis N, Mahaira L, Talieri M, Giannopoulos A, Iliadis K, Papaioannou D, Nasioulas G, Trangas T. (2004) Expression of the RNA-binding protein CRD-BP in brain and non-small cell lung tumors. *Cancer Lett.* ;209: 245-50.

*Impact factor 4, 54*

34. Pantou D, Rizou H, Tsarouha H, Pouli A, Papanastasiou K, Stamatellou M, Trangas T, Pandis N, Bardi G. (2005) Cytogenetic manifestations of multiple myeloma heterogeneity. *Genes Chromosomes Cancer*. 42:44-57.

*Impact factor: 3, 31*

35. Yannopoulos A, Dimitriadis E, Scorilas A, Trangas T, Markakis E, Talieri M. 2005 mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete *Br J Cancer*. 93:152-8

*Impact factor: 5, 04*

36. Dimitriadis E, **Trangas T**,\* Milatos S, Foukas PG, Gioulbasanis I, Courtis N, Nielsen FC, Pandis N, Dafni U, Bardi G, Ioannidis P. 2007 Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer. *Int J Cancer*.;121:486-94.

*Impact factor: 6, 18*

37. Dimitriadis, Rontogianni, Kyriazoglou<sup>1</sup> Takou A, Frangia K, Pandis N, **Trangas T** (2009) Novel SYT-SSX fusion transcript variants in Synovial Sarcomas *Cancer Genetics and Cytogenetics* 195 :54-8

*Impact factor: 1, 57*

38. Rapti A, **Trangas T**, Samiotaki M, Ioannidis P, Dimitriadis E, Meristoudis C, Veletza S, Courtis N (2010) The structure of the 5'-untranslated region of mammalian poly(A)



polymerase-alpha mRNA suggests a mechanism of translational regulation. *Mol Cell Biochem.* 340: 91-6.

Impact factor: **2,3**

39. Yavropoulou MP, Kotsa K, Gotzamani Psarrakou A, Papazisi A, **Tranga T**, Ventis S, Yovos JG. (2010 ) Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. *Hormones* (Athens). 9::274-8.

Impact factor: **2,44**

40. Stathopoulos GP, Armakolas A, **Tranga T**, Marinou H, Stathopoulos J, Chandrinou H. (2011) Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer. *Oncol Rep* 25:1541-4.

Impact factor: **1,588**

41. Katsori AM, Chatzopoulou M, Dimas K, Kontogiorgis C, Patsilidakos A, **Trangas T**, Hadjipavlou-Litina D (2011). Curcumin analogues as possible anti-proliferative & anti-inflammatory agents. *Eur J Med Chem.* 46:2722-35.

Impact factor: **3,269**

42. Trangas T, Ioannidis P. .( 2011); IGF2BP1 (insulin-like growth factor 2 mRNA binding protein 1). *Atlas Genet Cytogenet OncolHaematol*15(7):562-566.

- 43 Maladaki A Yavropoulou AP Kotsa K, **Tranga T**, Ventis, S . Yovos JG (2012) Non tumoral hyperserotoninaemia responsive to octreotide due to dual polymorphism in UGT1A1 and UGT1A6 *Hormones* (Athens) 11:104-108

Impact factor: **2,44**

- 44.Devetzi, M **Trangas**, T .Scorilas, A Xynopoulos, D .Taliari M, (2012) Parallel overexpression and clinical significance of Kallikrein-related peptidases 7 and 14 (KLK7 & KLK14) in colon cancer *Thrombosis and Haemostasis* 109:716-25.

Impact factor **6,09**

- 45.Dimitriadis E . Kalogeropoulos, T. Velaeti, S, Sotiriou, S, Vassiliou, E, Fasoulis, L, Klapsas, V Synesiou, M, Apostolaki, A **Trangas**, T; Pandis, N (2013) Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer *Anticancer Res.* 33:191-7

Impact factor **1, 71**

46. Pantazi D, Kitsioulis E, Karkabounas A, **Trangas T** Nakos G, Lekka, ME (2013) <sup>a</sup>Dipalmitoyl-phosphatidylcholine biosynthesis is induced by non-injurious mechanical stretch in a model of alveolar type II cells *Lipids* 48: 827-838.

Impact factor **2,13**

## GENE BANK deposits

1.AF263921

Homo sapiens mRNA binding protein CRD-BP/IMP-1 gene, promoter region

2.AF198255

Homo sapiens CRDBP gene intron

3.AF198254

Homo sapiens mRNA-binding protein CRDBP mRNA complete cDNA